{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T21:20:21Z","timestamp":1762377621180,"version":"3.37.3"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T00:00:00Z","timestamp":1729641600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T00:00:00Z","timestamp":1729641600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005366","name":"University of Oslo","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005366","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Osteoporos"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Summary<\/jats:title>\n                <jats:p>We aimed to investigate the risk of hip fracture associated with zoledronic acid treatment compared to alendronate on a population level. The risk of hip fracture was lower in women using zoledronic acid and higher in women who had discontinued treatment. The findings support the effectiveness of intravenous bisphosphonate.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>To investigate whether zoledronic acid (ZOL) was associated with a lower risk of the first hip fracture than alendronate (ALN) in Norway using real-world data.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Nationwide data on drugs dispensed in outpatient pharmacies were individually linked with all hospital-treated hip fractures. Individuals aged 50\u201389\u00a0years without previous hip fracture were included at their first filling of a prescription for ALN or ZOL during 2005\u20132016. Hazard ratios (HRs) with 95% confidence intervals (95% CIs) for first hip fracture by time-varying exposure to ZOL versus ALN were estimated in sex-stratified flexible parametric survival analyses. Covariates included time-varying accumulated ALN exposure and comorbidity level expressed by the prescription-based Rx-Risk Comorbidity Index, marital status, education, and residential urbanity.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Of 75,250 women who initiated treatment, 72,614 (96.5%) were exposed to ALN and 6366 (8.5%) to ZOL. Of 12,739 men who initiated treatment, 12,311 (96.6%) were exposed to ALN and 784 (6.2%) to ZOL. In women, the HR for first hip fracture was 0.75 (95% CI: 0.61\u20130.91) for ZOL versus ALN. In men, the corresponding HR was 0.59 (95% CI: 0.32\u20131.07). Discontinued treatment was associated with increased risk compared with current ALN treatment in women (HR: 1.33; 95% CI: 1.24\u20131.42, men: HR 1.13 (95% CI: 0.95\u20131.35)).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>In women, the risk of first hip fracture when treated with ZOL was 25% lower than when treated with ALN. Discontinued treatment was associated with a 33% increase in hip fracture risk. Similar, albeit statistically non-significant, results were observed in men.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s11657-024-01458-4","type":"journal-article","created":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T19:02:23Z","timestamp":1729710143000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Risk of first hip fracture under treatment with zoledronic acid versus alendronate: a NOREPOS cohort study of 88,000 Norwegian men and women in outpatient care"],"prefix":"10.1007","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3851-1386","authenticated-orcid":false,"given":"Brit Solvor Lyse","family":"Riska","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nina","family":"Gunnes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Trine E.","family":"Finnes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haakon E.","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mari","family":"Hoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tone K.","family":"Omsland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristin","family":"Holvik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,10,23]]},"reference":[{"key":"1458_CR1","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1007\/s00198-015-3154-6","volume":"26","author":"A Od\u00e9n","year":"2015","unstructured":"Od\u00e9n A, McCloskey EV, Kanis JA, Harvey NC, Johansson H (2015) Burden of high fracture probability worldwide: secular increases 2010\u20132040. Osteoporos Int 26:2243\u20132248","journal-title":"Osteoporos Int"},{"key":"1458_CR2","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1016\/S0140-6736(15)00516-4","volume":"387","author":"JR Beard","year":"2016","unstructured":"Beard JR, Officer A, de Carvalho IA et al (2016) The World report on ageing and health: a policy framework for healthy ageing. Lancet 387:2145\u20132154","journal-title":"Lancet"},{"key":"1458_CR3","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1007\/s11657-020-00871-9","volume":"16","author":"JA Kanis","year":"2021","unstructured":"Kanis JA, Norton N, Harvey NC, Jacobson T, Johansson H, Lorentzon M, McCloskey EV, Willers C, Borgstr\u00f6m F (2021) SCOPE 2021: a new scorecard for osteoporosis in Europe. Arch Osteoporos 16:82","journal-title":"Arch Osteoporos"},{"issue":"6","key":"1458_CR4","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/nrendo.2014.51","volume":"10","author":"JA Cauley","year":"2014","unstructured":"Cauley JA, Chalhoub D, Kassem AM, El-Hajj Fuleihan G (2014) Geographic and ethnic disparities in osteoporotic fractures. Nat Rev Endocrinol 10(6):338\u2013351","journal-title":"Nat Rev Endocrinol"},{"key":"1458_CR5","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1359\/JBMR.050304","volume":"20","author":"O Johnell","year":"2005","unstructured":"Johnell O, Kanis JA, Oden A et al (2005) Predictive value of BMD for hip and other fractures. J Bone Miner Res 20:1185\u20131194","journal-title":"J Bone Miner Res"},{"key":"1458_CR6","unstructured":"Sakshaug S (red) (2018) Drug consumption in Norway 2013\u20132017. Legemiddelstatistikk 2018:1. Norwegian Institute of Public Health, Oslo. https:\/\/www.fhi.no\/globalassets\/dokumenterfiler\/rapporter\/2018\/legemiddelforbruket-i-norge-2013-2017.pdf. Accessed 10 Oct 2024"},{"key":"1458_CR7","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1007\/s11606-021-06938-8","volume":"37","author":"SJ Cromer","year":"2022","unstructured":"Cromer SJ, D\u2019Silva KM, Yu EW, Landon J, Desai RJ, Kim SC (2022) Secular trends in the pharmacologic treatment of osteoporosis and malignancy-related bone disease from 2009 to 2020. J Gen Intern Med 37:1917\u20131924","journal-title":"J Gen Intern Med"},{"key":"1458_CR8","doi-asserted-by":"publisher","first-page":"4118","DOI":"10.1210\/jcem.85.11.6953","volume":"85","author":"DM Black","year":"2000","unstructured":"Black DM, Thompson DE, Bauer DC, Ensrud K, Musliner T, Hochberg MC, Nevitt MC, Suryawanshi S, Cummings SR (2000) Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab 85:4118\u20134124","journal-title":"J Clin Endocrinol Metab"},{"key":"1458_CR9","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa067312","volume":"356","author":"DM Black","year":"2007","unstructured":"Black DM, Delmas PD, Eastell R et al (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809\u20131822","journal-title":"N Engl J Med"},{"issue":"2","key":"1458_CR10","doi-asserted-by":"publisher","first-page":"182","DOI":"10.7326\/M22-0684","volume":"176","author":"C Ayers","year":"2023","unstructured":"Ayers C, Kansagara D, Lazur B et al (2023) Effectiveness and safety of treatments to prevent fractures in people with low bone mass or primary osteoporosis: a living systematic review and network meta-analysis for the American College of Physicians. Ann Intern Med 176(2):182\u2013195","journal-title":"Ann Intern Med"},{"key":"1458_CR11","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1002\/jbmr.1605","volume":"27","author":"S Boonen","year":"2012","unstructured":"Boonen S, Eastell R, Su G et al (2012) Time to onset of antifracture efficacy and year-by-year persistence of effect of zoledronic acid in women with osteoporosis. J Bone Miner Res 27:1487\u20131493","journal-title":"J Bone Miner Res"},{"key":"1458_CR12","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1001\/jamainternmed.2021.6745","volume":"182","author":"WJ Deardorff","year":"2022","unstructured":"Deardorff WJ, Cenzer I, Nguyen B, Lee SJ (2022) Time to benefit of bisphosphonate therapy for the prevention of fractures among postmenopausal women with osteoporosis: a meta-analysis of randomized clinical trials. JAMA Intern Med 182:33\u201341","journal-title":"JAMA Intern Med"},{"key":"1458_CR13","unstructured":"Uptodate.com The use of bisphosphonates in postmenopausal women with osteoporosis https:\/\/www.uptodate.com\/contents\/the-use-of-bisphosphonates-in-postmenopausal-women-with-osteoporosis?search=bisphosphonate%20therapy&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1#H1068767 Accessed 11.16.2020"},{"key":"1458_CR14","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s00198-011-1583-4","volume":"23","author":"P Hadji","year":"2012","unstructured":"Hadji P, Gamerdinger D, Spieler W, Kann PH, Loeffler H, Articus K, M\u00f6ricke R, Ziller V (2012) Rapid Onset and Sustained Efficacy (ROSE) study: results of a randomised, multicentre trial comparing the effect of zoledronic acid or alendronate on bone metabolism in postmenopausal women with low bone mass. Osteoporos Int 23:625\u2013633","journal-title":"Osteoporos Int"},{"key":"1458_CR15","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.semarthrit.2010.06.001","volume":"40","author":"JP Jansen","year":"2011","unstructured":"Jansen JP, Bergman GJ, Huels J, Olson M (2011) The efficacy of bisphosphonates in the prevention of vertebral, hip, and nonvertebral-nonhip fractures in osteoporosis: a network meta-analysis. Semin Arthritis Rheum 40:275-284.e-2","journal-title":"Semin Arthritis Rheum"},{"key":"1458_CR16","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s11657-017-0375-7","volume":"12","author":"L Karlsson","year":"2017","unstructured":"Karlsson L, Mesterton J, Tepie MF, Intorcia M, Overbeek J, Str\u00f6m O (2017) Exploring methods for comparing the real-world effectiveness of treatments for osteoporosis: adjusted direct comparisons versus using patients as their own control. Arch Osteoporos 12:81","journal-title":"Arch Osteoporos"},{"key":"1458_CR17","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.1007\/s00198-015-3148-4","volume":"26","author":"L Chen","year":"2015","unstructured":"Chen L, Wang G, Zheng F, Zhao H, Li H (2015) Efficacy of bisphosphonates against osteoporosis in adult men: a meta-analysis of randomized controlled trials. Osteoporos Int 26:2355\u20132363","journal-title":"Osteoporos Int"},{"key":"1458_CR18","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s40744-016-0030-6","volume":"3","author":"J Zhou","year":"2016","unstructured":"Zhou J, Wang T, Zhao X, Miller DR, Zhai S (2016) Comparative efficacy of bisphosphonates to prevent fracture in men with osteoporosis: a systematic review with network meta-analyses. Rheumatol Ther 3:117\u2013128","journal-title":"Rheumatol Ther"},{"key":"1458_CR19","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1002\/jbmr.119","volume":"25","author":"ES Orwoll","year":"2010","unstructured":"Orwoll ES, Miller PD, Adachi JD, Brown J, Adler RA, Kendler D, Bucci-Rechtweg C, Readie A, Mesenbrink P, Weinstein RS (2010) Efficacy and safety of a once-yearly i.v. Infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study. J Bone Miner Res 25:2239\u20132250","journal-title":"J Bone Miner Res"},{"key":"1458_CR20","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1007\/s00198-022-06350-w","volume":"33","author":"A Bastounis","year":"2022","unstructured":"Bastounis A, Langley T, Davis S, Paskins Z, Gittoes N, Leonardi-Bee J, Sahota O (2022) Comparing medication adherence in patients receiving bisphosphonates for preventing fragility fractures: a comprehensive systematic review and network meta-analysis. Osteoporos Int 33:1223\u20131233","journal-title":"Osteoporos Int"},{"key":"1458_CR21","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.4065\/81.8.1013","volume":"81","author":"ES Siris","year":"2006","unstructured":"Siris ES, Harris ST, Rosen CJ, Barr CE, Arvesen JN, Abbott TA, Silverman S (2006) Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 81:1013\u20131022","journal-title":"Mayo Clin Proc"},{"key":"1458_CR22","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1001\/archinte.160.4.517","volume":"160","author":"DC Bauer","year":"2000","unstructured":"Bauer DC, Black D, Ensrud K, Thompson D, Hochberg M, Nevitt M, Musliner T, Freedholm D, Group ftFITR (2000) Upper gastrointestinal tract safety profile of alendronate: the fracture intervention trial. Arch Intern Med 160:517\u2013525","journal-title":"Arch Intern Med"},{"key":"1458_CR23","doi-asserted-by":"publisher","first-page":"315","DOI":"10.2165\/00003088-199936050-00002","volume":"36","author":"AG Porras","year":"1999","unstructured":"Porras AG, Holland SD, Gertz BJ (1999) Pharmacokinetics of alendronate. Clin Pharmacokinet 36:315\u2013328","journal-title":"Clin Pharmacokinet"},{"key":"1458_CR24","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1093\/aje\/kwaa283","volume":"190","author":"M Webster-Clark","year":"2021","unstructured":"Webster-Clark M, Ross RK, Lund JL (2021) Initiator types and the causal question of the prevalent new-user design: a simulation study. Am J Epidemiol 190:1341\u20131348","journal-title":"Am J Epidemiol"},{"issue":"2","key":"1458_CR25","first-page":"129","volume":"18","author":"K Furu","year":"2009","unstructured":"Furu K (2009) Establishment of the nationwide Norwegian Prescription Database (NorPD) \u2013 new opportunities for research in pharmacoepidemiology in Norway. Norsk Epidemiologi 18(2):129\u2013136","journal-title":"Norsk Epidemiologi"},{"key":"1458_CR26","unstructured":"WHO Collaborating Centre for Drug Statistics Methodology. https:\/\/www.whocc.no\/. Accessed 10 Oct 2024"},{"key":"1458_CR27","unstructured":"The Norwegian Pharmaceutical Product Compendium (Felleskatalogen AS). https:\/\/www.felleskatalogen.no\/medisin\/. Accessed 10 Oct 2024"},{"key":"1458_CR28","doi-asserted-by":"publisher","first-page":"2927","DOI":"10.1001\/jama.296.24.2927","volume":"296","author":"DM Black","year":"2006","unstructured":"Black DM, Schwartz AV, Ensrud KE et al (2006) Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 296:2927\u20132938","journal-title":"JAMA"},{"key":"1458_CR29","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1002\/jbmr.1494","volume":"27","author":"DM Black","year":"2012","unstructured":"Black DM, Reid IR, Boonen S et al (2012) The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res 27:243\u2013254","journal-title":"J Bone Miner Res"},{"key":"1458_CR30","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1177\/1403494814551858","volume":"42","author":"AJ S\u00f8gaard","year":"2014","unstructured":"S\u00f8gaard AJ, Meyer HE, Emaus N, Grimnes G, Gjesdal CG, Forsmo S, Schei B, Tell GS (2014) Cohort profile: Norwegian Epidemiologic Osteoporosis Studies (NOREPOS). Scand J Public Health 42:804\u2013813","journal-title":"Scand J Public Health"},{"key":"1458_CR31","unstructured":"Statistics Norway (2003) Norwegian standard classification of education, revised 2000.  https:\/\/www.ssb.no\/a\/english\/publikasjoner\/pdf\/nos_c751_en\/nos_c751_en.pdf. Accessed 10 Oct 2024"},{"key":"1458_CR32","doi-asserted-by":"publisher","first-page":"e10236","DOI":"10.1002\/jbm4.10236","volume":"3","author":"SM Solbakken","year":"2019","unstructured":"Solbakken SM, Magnus JH, Meyer HE et al (2019) Urban-rural differences in hip fracture mortality: a nationwide NOREPOS Study. JBMR Plus 3:e10236","journal-title":"JBMR Plus"},{"key":"1458_CR33","doi-asserted-by":"publisher","first-page":"e057823","DOI":"10.1136\/bmjopen-2021-057823","volume":"12","author":"K Holvik","year":"2022","unstructured":"Holvik K, Hjellvik V, Karlstad \u00d8, Gunnes N, Hoff M, Tell GS, Meyer HE (2022) Contribution of an extensive medication-based comorbidity index (Rx-Risk) in explaining the excess mortality after hip fracture in older Norwegians: a NOREPOS cohort study. BMJ Open 12:e057823","journal-title":"BMJ Open"},{"key":"1458_CR34","first-page":"265","volume":"9","author":"PC Lambert","year":"2009","unstructured":"Lambert PC, Royston P (2009) Further development of flexible parametric models for survival analysis. Stand Genom Sci 9:265\u2013290","journal-title":"Stand Genom Sci"},{"issue":"2","key":"1458_CR35","doi-asserted-by":"publisher","first-page":"224","DOI":"10.7326\/M22-1034","volume":"176","author":"A Qaseem","year":"2023","unstructured":"Qaseem A, Hicks LA, Etxeandia-Ikobaltzeta I et al (2023) Pharmacologic treatment of primary osteoporosis or low bone mass to prevent fractures in adults: a living clinical guideline from the American College of Physicians. Ann Intern Med 176(2):224\u2013238","journal-title":"Ann Intern Med"},{"key":"1458_CR36","doi-asserted-by":"publisher","first-page":"37","DOI":"10.7326\/M19-0533","volume":"171","author":"HA Fink","year":"2019","unstructured":"Fink HA, MacDonald R, Forte ML et al (2019) Long-term drug therapy and drug discontinuations and holidays for osteoporosis fracture prevention: a systematic review. Ann Intern Med 171:37\u201350","journal-title":"Ann Intern Med"},{"key":"1458_CR37","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1007\/s00198-018-4560-3","volume":"29","author":"M Hoff","year":"2018","unstructured":"Hoff M, Skurtveit S, Meyer HE, Langhammer A, Sogaard AJ, Syversen U, Skovlund E, Abrahamsen B, Forsmo S, Schei B (2018) Anti-osteoporosis drug use: too little, too much, or just right? The HUNT study, Norway. Osteoporos Int 29:1875\u20131885","journal-title":"Osteoporos Int"},{"key":"1458_CR38","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s12916-024-03335-w","volume":"22","author":"SM Solbakken","year":"2024","unstructured":"Solbakken SM, Meyer HE, Dahl C, Finnes TE, Hjellvik V, Nielsen CS, Omsland TK, Stigum H, Holvik K (2024) The medication-based Rx-Risk Comorbidity Index and risk of hip fracture - a nationwide NOREPOS cohort study. BMC Med 22:118","journal-title":"BMC Med"},{"key":"1458_CR39","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1093\/aje\/kww011","volume":"184","author":"AJ S\u00f8gaard","year":"2016","unstructured":"S\u00f8gaard AJ, Holvik K, Omsland TK, Tell GS, Dahl C, Schei B, Meyer HE (2016) Age and sex differences in body mass index as a predictor of hip fracture: a NOREPOS Study. Am J Epidemiol 184:510\u2013519","journal-title":"Am J Epidemiol"},{"key":"1458_CR40","doi-asserted-by":"publisher","first-page":"e55077","DOI":"10.1371\/journal.pone.0055077","volume":"8","author":"X Tang","year":"2013","unstructured":"Tang X, Liu G, Kang J, Hou Y, Jiang F, Yuan W, Shi J (2013) Obesity and risk of hip fracture in adults: a meta-analysis of prospective cohort studies. PLoS ONE 8:e55077","journal-title":"PLoS ONE"},{"key":"1458_CR41","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1007\/s00198-005-1863-y","volume":"16","author":"C De Laet","year":"2005","unstructured":"De Laet C, Kanis JA, Od\u00e9n A et al (2005) Body mass index as a predictor of fracture risk: a meta-analysis. Osteoporos Int 16:1330\u20131338","journal-title":"Osteoporos Int"},{"key":"1458_CR42","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1016\/j.injury.2015.04.008","volume":"46","author":"GS Shen","year":"2015","unstructured":"Shen GS, Li Y, Zhao G, Zhou HB, Xie ZG, Xu W, Chen HN, Dong QR, Xu YJ (2015) Cigarette smoking and risk of hip fracture in women: a meta-analysis of prospective cohort studies. Injury 46:1333\u20131340","journal-title":"Injury"},{"key":"1458_CR43","doi-asserted-by":"publisher","first-page":"13148","DOI":"10.1038\/s41598-022-17536-x","volume":"12","author":"K Silventoinen","year":"2022","unstructured":"Silventoinen K, Piirtola M, Jelenkovic A et al (2022) Smoking remains associated with education after controlling for social background and genetic factors in a study of 18 twin cohorts. Sci Rep 12:13148","journal-title":"Sci Rep"},{"key":"1458_CR44","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.socscimed.2012.03.003","volume":"75","author":"A Ljungvall","year":"2012","unstructured":"Ljungvall A, Zimmerman FJ (2012) Bigger bodies: long-term trends and disparities in obesity and body-mass index among U.S. adults, 1960\u20132008. Soc Sci Med 75:109\u2013119","journal-title":"Soc Sci Med"},{"key":"1458_CR45","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1002\/jbmr.1476","volume":"27","author":"S Gehlbach","year":"2012","unstructured":"Gehlbach S, Saag KG, Adachi JD et al (2012) Previous fractures at multiple sites increase the risk for subsequent fractures: the Global Longitudinal Study of Osteoporosis in Women. J Bone Miner Res 27:645\u2013653","journal-title":"J Bone Miner Res"}],"container-title":["Archives of Osteoporosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11657-024-01458-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11657-024-01458-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11657-024-01458-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T12:11:27Z","timestamp":1734351087000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11657-024-01458-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,23]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1458"],"URL":"https:\/\/doi.org\/10.1007\/s11657-024-01458-4","relation":{},"ISSN":["1862-3514"],"issn-type":[{"type":"electronic","value":"1862-3514"}],"subject":[],"published":{"date-parts":[[2024,10,23]]},"assertion":[{"value":"17 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The study and data linkages have been approved by the Regional Committee for Medical and Health Research Ethics South East Norway (REC South East, reference number 15538), Statistics Norway, the Norwegian Directorate of Health, and the Norwegian Institute of Public Health. The data were handled in accordance with the General Data Protection Regulation, and a Data Protection Impact Assessment has been conducted in collaboration with the Data Protection Officer at the Norwegian Institute of Public Health. The study was based on national health registries to which reporting is mandatory and obtained exemption from confidentiality from REC South East, in accordance with the Norwegian Act on Medical and Health Research (the Health Research Act).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"None.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Data from the Norwegian Patient Registry have been used in this publication. The interpretation and reporting of these data are the sole responsibility of the authors, and no endorsement by the Norwegian Directorate of Health is intended nor should be inferred.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}}],"article-number":"102"}}